03 Collaborating with the Dermatology Community
Improving the quality of life of patients with skin diseases is at the heart of our purpose – we advance skin science and medical dermatology through research and development. By closely collaborating with key experts and the broad medical community, we build on each other’s expertise to create and implement strategic initiatives that address patient needs across the different stages of their journey.
SELECT A COUNTRY
United States
In 2024, we reached a pivotal milestone in our focus to advance dermatological care in the United States – bringing treatments to patients through a combination of scientific innovation, partnerships, evidence-based studies, and the launch of Klisyri® (tirbanibulin) 350 mg packets as a novel solution to treat actinic keratosis. Our efforts spanned three interconnected pillars: patient centricity, connections and clinical focus.
As part of our commitment to patient centricity, we hosted two panel sessions to deep–dive into patient connections and to better understand their backgrounds and how they cope with skin diseases. The session “Red Thread Connections” highlighted the importance of empathy and personal connection in delivering patient-centred care by focusing on insights from the patients closest to our teams including our own colleagues, friends and family. The other session focused on enabling meaningful dialogues between patients and dermatologists, ensuring a better understanding of their needs and treatment goals. Additionally, we launched a patient-centred campaign for Klisyri® (tirbanibulin), powered by patient data and dermatologist insights.
At an independent educational symposium held at the Annual AAD meeting, we focused on the importance of a patient-focused approach to educate and advance the field of treating actinic keratosis. This commitment to patients was further underscored by Real World Evidence studies such as PROSES and PROAK, which were supported by medical expert advocacy and new publications. In addition, we strengthened our connections with the dermatology community by hosting expert sessions, educational programmes such as Almirall ALLIES, and by attending relevant conferences in the dermatology industry. We fostered initiatives like the ‘Going Large Experience’, which enabled further feedback on the Klisyri® (tirbanibulin) 350 mg launch for continued improvements in the treatment of patients with AK. Our efforts extended through the distribution of nearly 200 Klisyri® (tirbanibulin) Launch Resource Kits via the Almirall Advantage Pharmacy network, reaching 500 dermatologists and supporting patient access to this game-changing treatment approach.
As part of our focus on advancing clinical research, our team shared six key publications of new clinical studies and had seven abstracts accepted at the American Academy of Dermatology (AAD) congress with four oral presentations about acne and actinic keratosis. In our commitment to advancing dermatological care and improving patient outcomes, we delivered over a dozen omnichannel assets and supported an expert consensus panel to demonstrate optimal approaches to field therapy in actinic keratosis.
Spain
Throughout 2024, we worked in close collaboration with the Academia Española de Dermatología y Venerología (AEDV) to design and deliver impactful initiatives aimed at upgrading the training infrastructure for future dermatologists. These programmes included the launch of training courses on clinical research – attended by over 75 researchers – and the development of educational support programmes for dermatologists, such as ENDERMA. Furthermore, we partnered with primary care societies to create independent educational courses addressing important research areas, including for the treatment of scalp psoriasis, actinic keratosis, and complex cases involving psoriasis in vulnerable patients or those with psoriasis resulting from oncological treatments.
Other key highlights include close collaborations with AEDV to support researchers in over 15 initiatives and involving over 50 clinical trial centres. Moreover, we’ve supported training programmes and symposia at national, regional and local congresses, and we’ve also initiated events and other activities to discuss the quality of the services offered in dermatology – always addressing patient needs and their well-being as our main priority.
Polonia
In 2024, we reached a pivotal milestone in our focus to advance dermatological care in the United States – bridging innovation to purpose through scientific communications, partnerships, evidence-based studies, and the launch of Klisyri® (tirbanibulin) 350 mg packets as an unprecedented solution to treat actinic keratosis. Our efforts spanned three interconnected pillars: patient centricity, connections and clinical focus.
As part of our commitment to patient centricity, we hosted two panel sessions to deep dive into patients’ connections and backgrounds. One entitled “Red Thread Connections” emphasizing the importance of empathy and personal connection in delivering patient-centred care by focusing on the patients closest to us including our own colleagues, friends, and family and the other session focused on meaningful dialogues between patients and dermatologists, ensuring a better understanding of their needs and goals. Additionally, we launched a patient-centred campaign for Klisyri® (tirbanibulin), powered by patient data and dermatologist.
Patients and customers remained the driving force behind our purpose. At the AAD Symposium, we emphasized the importance of a patient-focused approach to advance the field of actinic keratosis.
This commitment to patients was further underscored by evidence studies such as PROSES and PROAK, which were backed by medical expert advocacy and innovative publications. In addition, we also strengthened our connections with the dermatology community by hosting expert sessions, educational programmes such as Almirall ALLIES, and by attending relevant conferences in the dermatology industry. We fostered initiatives like the ‘Going Large Experience’, which enabled further feedback on the Klisyri® (tirbanibulin) 350 mg launch for continued development improvements. Our efforts extended through the distribution of nearly 200 Klisyri® (tirbanibulin) Launch Resource Kits via the Almirall Advantage Pharmacy network, reaching 500 dermatologists and ensuring patient access.
As our clinical focus remained steadfast this year, our team shared six key publications of new clinical studies and had seven abstracts accepted at the American Academy of Dermatology (AAD) congress with four oral presentations across acne and actinic keratosis. In our commitment to advancing dermatological care and improving patient outcomes, we delivered field therapy in actinic keratosis over a dozen omnichannel modalities and supported an expert consensus panel to demonstrate optimal approaches to field therapy in actinic keratosis.
Portugal
In 2024, we reached a pivotal milestone in our focus to advance dermatological care in the United States – bridging innovation to purpose through scientific communications, partnerships, evidence-based studies, and the launch of Klisyri® (tirbanibulin) 350 mg packets as an unprecedented solution to treat actinic keratosis. Our efforts spanned three interconnected pillars: patient centricity, connections and clinical focus.
As part of our commitment to patient centricity, we hosted two panel sessions to deep dive into patients’ connections and backgrounds. One entitled “Red Thread Connections” emphasizing the importance of empathy and personal connection in delivering patient-centred care by focusing on the patients closest to us including our own colleagues, friends, and family and the other session focused on meaningful dialogues between patients and dermatologists, ensuring a better understanding of their needs and goals. Additionally, we launched a patient-centred campaign for Klisyri® (tirbanibulin), powered by patient data and dermatologist.
Patients and customers remained the driving force behind our purpose. At the AAD Symposium, we emphasized the importance of a patient-focused approach to advance the field of actinic keratosis.
This commitment to patients was further underscored by evidence studies such as PROSES and PROAK, which were backed by medical expert advocacy and innovative publications. In addition, we also strengthened our connections with the dermatology community by hosting expert sessions, educational programmes such as Almirall ALLIES, and by attending relevant conferences in the dermatology industry. We fostered initiatives like the ‘Going Large Experience’, which enabled further feedback on the Klisyri® (tirbanibulin) 350 mg launch for continued development improvements. Our efforts extended through the distribution of nearly 200 Klisyri® (tirbanibulin) Launch Resource Kits via the Almirall Advantage Pharmacy network, reaching 500 dermatologists and ensuring patient access.
As our clinical focus remained steadfast this year, our team shared six key publications of new clinical studies and had seven abstracts accepted at the American Academy of Dermatology (AAD) congress with four oral presentations across acne and actinic keratosis. In our commitment to advancing dermatological care and improving patient outcomes, we delivered field therapy in actinic keratosis over a dozen omnichannel modalities and supported an expert consensus panel to demonstrate optimal approaches to field therapy in actinic keratosis.
Italy
In Italy we also focused on cross-functional collaboration with leading experts as there are significant opportunities for further expanding treatment options and growth in medical dermatology. Our activities aimed at providing product offerings tailored to local needs. In 2024, we hosted several events designed to promote a culture of continuous learning and professional development within the field of dermatology.
Eclipse focused on the management needs in atopic dermatitis, and we held five workshops in 5 cities across Italy – supported by 17 centres, 31 clinicians and 8 hospital pharmacists. The main goal was to understand how optimise the processes involved in the treatment of patients and focussing on their unmet needs. More than 70 solutions were identified, deriving in 30 project proposals and key actions.
Another key opportunity was Positivity, a stand-alone event held in Florence created to discuss the opportunities for treating patients with psoriasis with advanced biologics such as Ilumetri® (tildrakizumab) and to build a shared-approach to treatment that considers the needs of both patients and healthcare professionals. This state-of-the-art event positioned Almirall at the forefront of utilizing novel technology solutions at conventions, due to the use of an avatar to simulate clinical cases and interactive tools stimulating a self-analysis for the optimization of the doctor-patient relationship.
We also promoted A Skin Side, a national event aimed to shed light on how our products can contribute to the treatment of actinic keratosis and mild to moderate psoriasis. The objectives of this initiative were to educate on the added therapeutic value of Klisyri® (tirbanibulin) as well as to show healthcare professionals and key opinion leaders the distinctive properties of Wynzora® cream (calcipotriene and betamethasone dipropionate). A combination of lectures and practical sensory tests enabled to balance theory and clinical practice.
Switzerland
In 2024, we reached a pivotal milestone in our focus to advance dermatological care in the United States – bridging innovation to purpose through scientific communications, partnerships, evidence-based studies, and the launch of Klisyri® (tirbanibulin) 350 mg packets as an unprecedented solution to treat actinic keratosis. Our efforts spanned three interconnected pillars: patient centricity, connections and clinical focus.
As part of our commitment to patient centricity, we hosted two panel sessions to deep dive into patients’ connections and backgrounds. One entitled “Red Thread Connections” emphasizing the importance of empathy and personal connection in delivering patient-centred care by focusing on the patients closest to us including our own colleagues, friends, and family and the other session focused on meaningful dialogues between patients and dermatologists, ensuring a better understanding of their needs and goals. Additionally, we launched a patient-centred campaign for Klisyri® (tirbanibulin), powered by patient data and dermatologist.
Patients and customers remained the driving force behind our purpose. At the AAD Symposium, we emphasized the importance of a patient-focused approach to advance the field of actinic keratosis.
This commitment to patients was further underscored by evidence studies such as PROSES and PROAK, which were backed by medical expert advocacy and innovative publications. In addition, we also strengthened our connections with the dermatology community by hosting expert sessions, educational programmes such as Almirall ALLIES, and by attending relevant conferences in the dermatology industry. We fostered initiatives like the ‘Going Large Experience’, which enabled further feedback on the Klisyri® (tirbanibulin) 350 mg launch for continued development improvements. Our efforts extended through the distribution of nearly 200 Klisyri® (tirbanibulin) Launch Resource Kits via the Almirall Advantage Pharmacy network, reaching 500 dermatologists and ensuring patient access.
As our clinical focus remained steadfast this year, our team shared six key publications of new clinical studies and had seven abstracts accepted at the American Academy of Dermatology (AAD) congress with four oral presentations across acne and actinic keratosis. In our commitment to advancing dermatological care and improving patient outcomes, we delivered field therapy in actinic keratosis over a dozen omnichannel modalities and supported an expert consensus panel to demonstrate optimal approaches to field therapy in actinic keratosis.
France
To further build our engagement within medical dermatology in France, we worked with top experts, senior and younger dermatologists. We collaborated with young dermatologists delivering a symposium at the national congress JNPD, explaining the technologies and benefits of Ilumetri® (tildrakizumab) and Ebglyss® (lebrikizumab) in an event entitled “Between the burden of disease and the hope of a regained well-being: lessons from 3 chronic inflammatory dermatoses (Psoriasis, atopic dermatitis and hidradenitis suppurativa)”.
We also held a successful first session of our masterclass programme with three distinguished speakers: Prof. Bagot, Prof. Bergmann and Dr. Pavlovic. This session was entitled “The place of the dermatologist in the development of a medication: from research to prescription”. 15 young dermatologists and future leaders in dermatology attended and appreciated this first interactive session. The next session planned will be dedicated to AI and new imaging technologies in dermatology.
The latest clinical data of Ilumetri® (tildrakizumab) and Ebglyss® (lebrikizumab) were unveiled by Prof. Seneschal and Dr. Reguiai during an Almirall scientific event organized in Bordeaux in May of 2024 with more than 100 dermatologists in attendance. Moreover, we organized national and regional medical ad boards this year to exchange the last scientific news in the field of psoriasis/AD with the most relevant medical experts and to interpret our clinical data (lebrikizumab) and RWE (tildrakizumab).
To generate RWE data for tildrakizumab, we engaged more than 30 investigator sites with top opinion leaders and treating 160 patients in the ZODIPSO phase IV study (focusing on the difficult-to-treat areas of psoriasis such as scalp, genital, nail and palmoplantar), surpassing the initial target for the study. We also prepared the next NIS with tildrakizumab to investigate the efficacy of tildrakizumab 200 mg dosage in complex patients and its potential down-titration in case of disease control: TILFLEX study.
For Lebrikizumab, our teams engaged with 28 centres of excellence in the management of AD to develop clinical experience with the product before the launch. These interactions enabled the creation of critical insights from investigators regarding AD efficacy and control with lebrikizumab.
At this year’s national Journées Dermatologiques de Paris (JDP) congress, three highly recognized speakers from the Groupe de Recherche sur L’eczéma Atopique (GREAT) and Reso Dermatology societies communicated the latest news on the management of atopic dermatitis and explained the mechanism of action and long-term efficacy and safety data of Ebglyss® (lebrikizumab) to a large number of attendees. 3 tildrakizumab posters (the first POSITIVE study results) and 2 Lebrikizumab (ADvocate and ADvantage trial results) were accepted at the 2024 JDP congress.
We maintained our partnership with the GREAT group of the French Society of Dermatology who are responsible for the update of French guidelines in the management of AD and as they are building the first registry for collecting real-life data of AD patients on systemic treatments in France. Through our activities, Ebglyss® (lebrikizumab) has been included in the new AD guidelines unveiled at the JDP congress in December, in addition to established treatments like dupilumab, tralokinumab, and JAKis.
United Kingdom
In the United Kingdom we supported patients and the dermatology community through a number of important activities to provide better treatment options based on our strong presence in medical dermatology. In 2024, we continued our close partnerships with national and international dermatology experts, key opinion leaders and registrars to design and execute key initiatives that set new standards and deliver impactful results poised to break new ground in dermatology.
Key highlights include securing successful reimbursement agreements with the National Institute for Health and Care Excellence (NICE) and technology appraisals from the Scottish Medicines Consortium (SMC) for the launch of Ebglyss® (lebrikizumab). We reached 300 dermatology experts through strategic educational meetings for dermatology doctors, nurses and pharmacists at two DermaExchange meetings, Spring EADV, and a symposium at the British Association of Dermatology congress.
These events enabled sharing data and insights on the treatment of AD and consequently led to the creation of content and visuals to support education about these diseases as well as the benefits of advanced treatments.
We also initiated mentoring activities for the next generation of dermatology leaders by hosting a Specialty Certificate Examination (SCE) training weekend for 70 registrars – equipping them with the required knowledge and skills to become future consultants in the field. Other initiatives include attending a variety of congresses to promote connections with leading dermatologists and secure future partnerships. We engaged over 100 consultant-dermatologists-in-training through the programme, helping us further build our position as a key partner in dermatology in the UK.
Belgium
In 2024, we reached a pivotal milestone in our focus to advance dermatological care in the United States – bridging innovation to purpose through scientific communications, partnerships, evidence-based studies, and the launch of Klisyri® (tirbanibulin) 350 mg packets as an unprecedented solution to treat actinic keratosis. Our efforts spanned three interconnected pillars: patient centricity, connections and clinical focus.
As part of our commitment to patient centricity, we hosted two panel sessions to deep dive into patients’ connections and backgrounds. One entitled “Red Thread Connections” emphasizing the importance of empathy and personal connection in delivering patient-centred care by focusing on the patients closest to us including our own colleagues, friends, and family and the other session focused on meaningful dialogues between patients and dermatologists, ensuring a better understanding of their needs and goals. Additionally, we launched a patient-centred campaign for Klisyri® (tirbanibulin), powered by patient data and dermatologist.
Patients and customers remained the driving force behind our purpose. At the AAD Symposium, we emphasized the importance of a patient-focused approach to advance the field of actinic keratosis.
This commitment to patients was further underscored by evidence studies such as PROSES and PROAK, which were backed by medical expert advocacy and innovative publications. In addition, we also strengthened our connections with the dermatology community by hosting expert sessions, educational programmes such as Almirall ALLIES, and by attending relevant conferences in the dermatology industry. We fostered initiatives like the ‘Going Large Experience’, which enabled further feedback on the Klisyri® (tirbanibulin) 350 mg launch for continued development improvements. Our efforts extended through the distribution of nearly 200 Klisyri® (tirbanibulin) Launch Resource Kits via the Almirall Advantage Pharmacy network, reaching 500 dermatologists and ensuring patient access.
As our clinical focus remained steadfast this year, our team shared six key publications of new clinical studies and had seven abstracts accepted at the American Academy of Dermatology (AAD) congress with four oral presentations across acne and actinic keratosis. In our commitment to advancing dermatological care and improving patient outcomes, we delivered field therapy in actinic keratosis over a dozen omnichannel modalities and supported an expert consensus panel to demonstrate optimal approaches to field therapy in actinic keratosis.
Netherlands
In 2024, we reached a pivotal milestone in our focus to advance dermatological care in the United States – bridging innovation to purpose through scientific communications, partnerships, evidence-based studies, and the launch of Klisyri® (tirbanibulin) 350 mg packets as an unprecedented solution to treat actinic keratosis. Our efforts spanned three interconnected pillars: patient centricity, connections and clinical focus.
As part of our commitment to patient centricity, we hosted two panel sessions to deep dive into patients’ connections and backgrounds. One entitled “Red Thread Connections” emphasizing the importance of empathy and personal connection in delivering patient-centred care by focusing on the patients closest to us including our own colleagues, friends, and family and the other session focused on meaningful dialogues between patients and dermatologists, ensuring a better understanding of their needs and goals. Additionally, we launched a patient-centred campaign for Klisyri® (tirbanibulin), powered by patient data and dermatologist.
Patients and customers remained the driving force behind our purpose. At the AAD Symposium, we emphasized the importance of a patient-focused approach to advance the field of actinic keratosis.
This commitment to patients was further underscored by evidence studies such as PROSES and PROAK, which were backed by medical expert advocacy and innovative publications. In addition, we also strengthened our connections with the dermatology community by hosting expert sessions, educational programmes such as Almirall ALLIES, and by attending relevant conferences in the dermatology industry. We fostered initiatives like the ‘Going Large Experience’, which enabled further feedback on the Klisyri® (tirbanibulin) 350 mg launch for continued development improvements. Our efforts extended through the distribution of nearly 200 Klisyri® (tirbanibulin) Launch Resource Kits via the Almirall Advantage Pharmacy network, reaching 500 dermatologists and ensuring patient access.
As our clinical focus remained steadfast this year, our team shared six key publications of new clinical studies and had seven abstracts accepted at the American Academy of Dermatology (AAD) congress with four oral presentations across acne and actinic keratosis. In our commitment to advancing dermatological care and improving patient outcomes, we delivered field therapy in actinic keratosis over a dozen omnichannel modalities and supported an expert consensus panel to demonstrate optimal approaches to field therapy in actinic keratosis.
Germany
Our collaboration with the Professional Association of German Dermatologists e.V. (BVDD) was a key partnership to strengthen our commitment to advancing patient care in Germany. During 2024, we enhanced this collaboration through several initiatives, including the ‘Please Touch’ campaigns advocating support for Atopic Dermatitis and Psoriasis, as well as ’Together Against Skin Cancer’ and the sponsorship of Euromelanoma 2024 – aiming to raise awareness and improve treatment quality and success. Additionally, we supported local activations of key global events such as World Psoriasis Day and World Atopic Eczema Day in collaboration with BVDD.
Beyond these initiatives, we actively engaged with a number of other dermatology organizations like the Skin Network as well as PsoNet and the Society for Dermopharmacy e.V. and Onkoderm, in line with our dedication to early detection, innovation and improved therapeutic outcomes for patients.
Nordics
During 2024, we further built our partnerships and continued education in medical dermatology by supporting national and regional meetings across Sweden, Denmark and Norway including the International Federation of Psoriasis Associations conference.
National and regional events across the Nordics included six dermatology educational meetings in Sweden (including the Private Dermatologist Association annual meeting, resident doctor days in Dermatology, and three regional dermatology meetings across the country), three national meetings in Denmark, and one national meeting for Norwegian dermatologists.
Importantly, we also developed three large innovative stand–alone educational events with and for dermatologists in all three Nordic countries, which were highly appreciated by both delegates and the international expert speakers. Finally, we launched a ground-breaking, digital educational platform, pockettools.almirallmed.se, that provides a one-stop-shop of essential clinical tools and educational materials and is evolving constantly based on direct input from clinicians.
Austria
In 2024, we reached a pivotal milestone in our focus to advance dermatological care in the United States – bridging innovation to purpose through scientific communications, partnerships, evidence-based studies, and the launch of Klisyri® (tirbanibulin) 350 mg packets as an unprecedented solution to treat actinic keratosis. Our efforts spanned three interconnected pillars: patient centricity, connections and clinical focus.
As part of our commitment to patient centricity, we hosted two panel sessions to deep dive into patients’ connections and backgrounds. One entitled “Red Thread Connections” emphasizing the importance of empathy and personal connection in delivering patient-centred care by focusing on the patients closest to us including our own colleagues, friends, and family and the other session focused on meaningful dialogues between patients and dermatologists, ensuring a better understanding of their needs and goals. Additionally, we launched a patient-centred campaign for Klisyri® (tirbanibulin), powered by patient data and dermatologist.
Patients and customers remained the driving force behind our purpose. At the AAD Symposium, we emphasized the importance of a patient-focused approach to advance the field of actinic keratosis.
This commitment to patients was further underscored by evidence studies such as PROSES and PROAK, which were backed by medical expert advocacy and innovative publications. In addition, we also strengthened our connections with the dermatology community by hosting expert sessions, educational programmes such as Almirall ALLIES, and by attending relevant conferences in the dermatology industry. We fostered initiatives like the ‘Going Large Experience’, which enabled further feedback on the Klisyri® (tirbanibulin) 350 mg launch for continued development improvements. Our efforts extended through the distribution of nearly 200 Klisyri® (tirbanibulin) Launch Resource Kits via the Almirall Advantage Pharmacy network, reaching 500 dermatologists and ensuring patient access.
As our clinical focus remained steadfast this year, our team shared six key publications of new clinical studies and had seven abstracts accepted at the American Academy of Dermatology (AAD) congress with four oral presentations across acne and actinic keratosis. In our commitment to advancing dermatological care and improving patient outcomes, we delivered field therapy in actinic keratosis over a dozen omnichannel modalities and supported an expert consensus panel to demonstrate optimal approaches to field therapy in actinic keratosis.
Czechia
In 2024, we reached a pivotal milestone in our focus to advance dermatological care in the United States – bridging innovation to purpose through scientific communications, partnerships, evidence-based studies, and the launch of Klisyri® (tirbanibulin) 350 mg packets as an unprecedented solution to treat actinic keratosis. Our efforts spanned three interconnected pillars: patient centricity, connections and clinical focus.
As part of our commitment to patient centricity, we hosted two panel sessions to deep dive into patients’ connections and backgrounds. One entitled “Red Thread Connections” emphasizing the importance of empathy and personal connection in delivering patient-centred care by focusing on the patients closest to us including our own colleagues, friends, and family and the other session focused on meaningful dialogues between patients and dermatologists, ensuring a better understanding of their needs and goals. Additionally, we launched a patient-centred campaign for Klisyri® (tirbanibulin), powered by patient data and dermatologist.
Patients and customers remained the driving force behind our purpose. At the AAD Symposium, we emphasized the importance of a patient-focused approach to advance the field of actinic keratosis.
This commitment to patients was further underscored by evidence studies such as PROSES and PROAK, which were backed by medical expert advocacy and innovative publications. In addition, we also strengthened our connections with the dermatology community by hosting expert sessions, educational programmes such as Almirall ALLIES, and by attending relevant conferences in the dermatology industry. We fostered initiatives like the ‘Going Large Experience’, which enabled further feedback on the Klisyri® (tirbanibulin) 350 mg launch for continued development improvements. Our efforts extended through the distribution of nearly 200 Klisyri® (tirbanibulin) Launch Resource Kits via the Almirall Advantage Pharmacy network, reaching 500 dermatologists and ensuring patient access.
As our clinical focus remained steadfast this year, our team shared six key publications of new clinical studies and had seven abstracts accepted at the American Academy of Dermatology (AAD) congress with four oral presentations across acne and actinic keratosis. In our commitment to advancing dermatological care and improving patient outcomes, we delivered field therapy in actinic keratosis over a dozen omnichannel modalities and supported an expert consensus panel to demonstrate optimal approaches to field therapy in actinic keratosis.
Slovakia
In 2024, we reached a pivotal milestone in our focus to advance dermatological care in the United States – bridging innovation to purpose through scientific communications, partnerships, evidence-based studies, and the launch of Klisyri® (tirbanibulin) 350 mg packets as an unprecedented solution to treat actinic keratosis. Our efforts spanned three interconnected pillars: patient centricity, connections and clinical focus.
As part of our commitment to patient centricity, we hosted two panel sessions to deep dive into patients’ connections and backgrounds. One entitled “Red Thread Connections” emphasizing the importance of empathy and personal connection in delivering patient-centred care by focusing on the patients closest to us including our own colleagues, friends, and family and the other session focused on meaningful dialogues between patients and dermatologists, ensuring a better understanding of their needs and goals. Additionally, we launched a patient-centred campaign for Klisyri® (tirbanibulin), powered by patient data and dermatologist.
Patients and customers remained the driving force behind our purpose. At the AAD Symposium, we emphasized the importance of a patient-focused approach to advance the field of actinic keratosis.
This commitment to patients was further underscored by evidence studies such as PROSES and PROAK, which were backed by medical expert advocacy and innovative publications. In addition, we also strengthened our connections with the dermatology community by hosting expert sessions, educational programmes such as Almirall ALLIES, and by attending relevant conferences in the dermatology industry. We fostered initiatives like the ‘Going Large Experience’, which enabled further feedback on the Klisyri® (tirbanibulin) 350 mg launch for continued development improvements. Our efforts extended through the distribution of nearly 200 Klisyri® (tirbanibulin) Launch Resource Kits via the Almirall Advantage Pharmacy network, reaching 500 dermatologists and ensuring patient access.
As our clinical focus remained steadfast this year, our team shared six key publications of new clinical studies and had seven abstracts accepted at the American Academy of Dermatology (AAD) congress with four oral presentations across acne and actinic keratosis. In our commitment to advancing dermatological care and improving patient outcomes, we delivered field therapy in actinic keratosis over a dozen omnichannel modalities and supported an expert consensus panel to demonstrate optimal approaches to field therapy in actinic keratosis.
